Technology
Health
Pharmaceutical

Zomedica Pharmaceuticals

$0.722
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Pre-Market
$0.00 (0.00%) Pre-Market

Why Robinhood?

You can buy or sell ZOM and other stocks, options, ETFs, and crypto commission-free!

About

Zomedica Pharmaceuticals Corp. engages in the discovery, development and commercialization of pharmaceuticals for the companion pet. The company was founded by Gerald L. Read More Solensky, Jr. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Employees
27
Headquarters
Ann Arbor, Michigan
Founded
2013
Market Cap
70.47M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
58.21K
High Today
$0.8272
Low Today
$0.73
Open Price
$0.8272
Volume
6.74K
52 Week High
$2.98
52 Week Low
$0.5918

Collections

Technology
Health
Pharmaceutical
2017 IPO
US
North America

News

MarketBeatMar 5

Stock Price, News, & Analysis for Zomedica Pharmaceuticals

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transder...

1
Markets InsiderFeb 26

Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results

ANN ARBOR, Mich., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). “We made major strides in 2018 to expand our diagnostic pi...

94

Earnings

-$0.09
-$0.07
-$0.04
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.